<DOC>
	<DOCNO>NCT02332668</DOCNO>
	<brief_summary>This 2-part study pembrolizumab ( MK-3475 ) pediatric participant either advanced melanoma program cell death ligand 1 ( PD-L1 ) -positive advance , relapse refractory solid tumor lymphoma . Part 1 find maximum tolerate dose ( MTD ) /maximum administer dose ( MAD ) , confirm dose , find recommended Phase 2 dose ( RP2D ) pembrolizumab therapy . Part 2 evaluate safety efficacy pediatric RP2D .</brief_summary>
	<brief_title>A Study Pembrolizumab ( MK-3475 ) Pediatric Participants With Advanced Melanoma Advanced , Relapsed , Refractory PD-L1-Positive Solid Tumors Lymphoma ( MK-3475-051/KEYNOTE-051 )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Between 6 month le 18 year age day sign inform consent/assent ( first 3 participant dose Part 1 &gt; = 6 year age ) Histologically cytologicallydocumented , locallyadvanced , metastatic solid malignancy lymphoma incurable fail prior standard therapy , standard therapy exists , standard therapy consider appropriate Any number prior treatment regimen Tissue available archival tissue sample , appropriate , newly obtain core excisional biopsy tumor lesion previously irradiate Advanced melanoma PDL1positive advance , relapse , refractory solid tumor lymphoma Measurable disease base RECIST 1.1 Participants neuroblastoma metaiodobenzylguanidine ( MIBG ) positive evaluable disease may enrol Lansky Play Scale ≥50 participant 6 month include 16 year age ; Karnofsky score ≥50 participant &gt; 16 year age Adequate organ function Female participant childbearing potential negative urine serum pregnancy test within 72 hour prior receive first dose study medication Female participant childbearing potential must willing use 2 method contraception surgically sterile , abstain heterosexual activity course study 120 day last dose study medication Male participant must agree use adequate method contraception start first dose study medication 120 day last dose study medication Currently participate receive study therapy , participate study investigational agent receive study therapy use investigational device within 4 week first dose study medication Diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study medication Anticancer monoclonal antibody ( mAb ) within 4 week prior study Day 1 recover adverse event due mAbs administer 4 week earlier Prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 recover adverse event due previously administer agent Known additional malignancy progress require active treatment exception basal cell carcinoma skin , squamous cell carcinoma skin potentially curative therapy , situ cervical cancer Known active central nervous system ( CNS ) metastases and/or carcinomatous meningitis Tumor ( ) involve brain stem Active autoimmune disease require systemic treatment past 2 year ; replacement therapy ( thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency ) acceptable Has history ( noninfectious ) pneumonitis require steroid current pneumonitis . Active infection require systemic therapy Pregnant breastfeeding , expect conceive father child within project duration trial 120 day last dose study medication Prior therapy antiprogrammed cell death ( PD ) 1 , antiPD ligand 1 ( L1 ) , anticytotoxic T lymphocyteassociated protein 4 ( CTLA4 ) agent , antibody drug specifically target Tcell costimulation checkpoint pathway Human immunodeficiency virus ( HIV ) Hepatitis B C Received live vaccine within 30 day plan start study medication Has undergone solid organ transplant time , prior allogeneic hematopoietic stem cell transplantation within last 5 year . ( Participants transplant &gt; 5 year ago eligible long symptom Graft Versus Host Disease [ GVHD ] . ) History current evidence condition , therapy , laboratory abnormality , know severe hypersensitivity component analog trial treatment , might confound result trial , interfere participant 's participation full duration trial Known psychiatric substance abuse disorder would interfere requirement trial</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
</DOC>